RT Journal Article SR Electronic T1 Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Gastroesophageal Adenocarcinoma JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 1035 OP 1039 VO 33 IS 3 A1 URSULA PLUSCHNIG A1 SEBASTIAN F. SCHOPPMANN A1 MATTHIAS PREUSSER A1 PHILIP DATLER A1 REZA ASARI A1 AHMED BA-SSALAMAH A1 KATRIN SCHWAMEIS A1 PETER BIRNER A1 JOHANNES ZACHERL A1 MICHAEL HEJNA YR 2013 UL http://ar.iiarjournals.org/content/33/3/1035.abstract AB Background: The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma. Therefore, we aimed to establish a modified version of the EOX regimen with improved tolerability for these patients. Patients and Methods: Patients received palliative first-line chemotherapy with a modified EOX regimen repeated every three weeks (epirubicin 50 mg/m2 i.v., day 1; oxaliplatin 130 mg/m2 i.v., day 1; capecitabine at a twice-daily dose of 1000 mg/m2 p.o. for two weeks). Results: Out of 51 patients, partial remission was observed in five (10.2%) and stable disease in 31 (60.8%). Progression-free survival was four months, and overall survival twelve months. Conclusion: Modified EOX was generally well-tolerated and, therefore, further investigation within prospective clinical trials is warranted.